Nifty
Sensex
:
:
10482.20
34812.99
-103.00 (-0.97%)
-345.56 (-0.98%)

Pharmaceuticals & Drugs

Rating :
74/99

BSE: 524500 | NSE: KILITCH

185.55
-15.65 (-7.78%)
12-Nov-2018 | 3:58PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  201.40
  •  201.85
  •  183.10
  •  201.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  148928
  •  276.34
  •  208.80
  •  71.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 308.87
  • 24.26
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 305.02
  • 0.25%
  • 2.19

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.25%
  • 0.79%
  • 25.65%
  • FII
  • DII
  • Others
  • 0%
  • 0.00%
  • 4.31%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -8.96
  • 27.63
  • 33.90

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -13.49
  • -
  • -

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -5.69
  • 39.35
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.88
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.61
  • 0.56
  • 0.72

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 29.56
  • 44.36
  • 70.55

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Sep 17
Sep 16
Var%
Net Sales
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBITDA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Depreciation
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PBT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 12
Mar 11
Mar 10
Net Sales
-
51.01
28.65
20.99
19.03
107.96
146.30
142.66
Net Sales Growth
-
78.05%
36.49%
10.30%
-82.37%
-26.21%
2.55%
 
Cost Of Goods Sold
-
26.00
11.25
8.73
7.02
71.19
100.27
98.28
Gross Profit
-
25.01
17.39
12.25
12.01
36.78
46.03
44.38
GP Margin
-
49.03%
60.70%
58.36%
63.11%
34.07%
31.46%
31.11%
Total Expenditure
-
45.71
29.20
25.29
20.79
95.34
124.23
118.99
Power & Fuel Cost
-
1.15
1.10
0.97
0.82
6.35
6.56
4.82
% Of Sales
-
2.25%
3.84%
4.62%
4.31%
5.88%
4.48%
3.38%
Employee Cost
-
4.30
3.38
3.47
3.13
6.44
5.62
4.10
% Of Sales
-
8.43%
11.80%
16.53%
16.45%
5.97%
3.84%
2.87%
Manufacturing Exp.
-
2.18
2.73
2.68
1.66
5.98
7.60
7.38
% Of Sales
-
4.27%
9.53%
12.77%
8.72%
5.54%
5.19%
5.17%
General & Admin Exp.
-
3.27
2.80
2.71
2.52
2.04
1.88
1.92
% Of Sales
-
6.41%
9.77%
12.91%
13.24%
1.89%
1.29%
1.35%
Selling & Distn. Exp.
-
5.22
4.71
3.46
2.00
2.02
1.47
1.57
% Of Sales
-
10.23%
16.44%
16.48%
10.51%
1.87%
1.00%
1.10%
Miscellaneous Exp.
-
3.59
3.21
3.27
3.64
1.32
0.83
0.92
% Of Sales
-
7.04%
11.20%
15.58%
19.13%
1.22%
0.57%
0.64%
EBITDA
-
5.30
-0.55
-4.30
-1.76
12.62
22.07
23.67
EBITDA Margin
-
10.39%
-1.92%
-20.49%
-9.25%
11.69%
15.09%
16.59%
Other Income
-
3.27
1.14
2.78
2.72
1.06
0.17
0.48
Interest
-
0.42
0.16
0.06
0.05
2.96
3.54
4.53
Depreciation
-
2.04
9.76
10.05
1.85
4.87
5.59
6.07
PBT
-
6.11
-9.32
-11.63
-0.95
5.84
13.12
13.55
Tax
-
0.96
-0.43
-0.44
-0.66
21.05
2.63
2.81
Tax Rate
-
15.71%
4.61%
3.78%
69.47%
21.62%
20.05%
20.74%
PAT
-
5.15
-8.89
-11.19
-0.29
76.87
10.56
10.74
PAT before Minority Interest
-
5.15
-8.89
-11.19
-0.29
76.31
10.49
10.74
Minority Interest
-
0.00
0.00
0.00
0.00
0.56
0.07
0.00
PAT Margin
-
10.10%
-31.03%
-53.31%
-1.52%
71.20%
7.22%
7.53%
PAT Growth
-
-
-
-
-
627.94%
-1.68%
 
Unadjusted EPS
-
3.89
-6.72
-8.46
-0.22
57.67
7.92
7.74

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 12
Mar 11
Mar 10
Shareholder's Funds
112.03
101.20
108.69
119.88
114.55
84.31
75.15
Share Capital
13.73
13.23
13.23
13.23
13.23
13.23
13.20
Total Reserves
94.56
86.59
94.08
105.27
99.94
69.20
59.88
Non-Current Liabilities
-1.55
-2.47
-0.95
-0.51
0.82
0.89
38.48
Secured Loans
0.00
0.00
0.00
0.00
0.04
0.00
42.99
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.01
0.00
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
14.92
11.69
7.99
6.85
60.47
66.23
21.18
Trade Payables
7.72
5.68
3.69
2.39
3.66
10.25
11.83
Other Current Liabilities
3.50
3.22
3.35
3.92
1.33
38.00
2.16
Short Term Borrowings
0.92
0.69
0.19
0.00
8.77
15.63
0.00
Short Term Provisions
2.78
2.11
0.77
0.55
46.71
2.35
7.19
Total Liabilities
126.13
110.42
115.73
126.22
176.92
153.00
134.81
Net Block
32.96
33.31
42.41
9.38
8.64
41.93
44.26
Gross Block
67.97
66.28
65.62
22.55
20.78
74.27
70.99
Accumulated Depreciation
35.01
32.97
23.21
13.16
12.14
32.34
26.73
Non Current Assets
63.14
61.85
68.43
79.48
9.61
85.48
67.38
Capital Work in Progress
3.18
0.66
0.00
0.00
0.00
43.15
22.11
Non Current Investment
26.00
27.01
25.82
47.16
0.72
0.22
1.02
Long Term Loans & Adv.
0.22
0.08
0.20
22.94
0.25
0.19
0.00
Other Non Current Assets
0.79
0.79
0.00
0.00
0.00
0.00
0.00
Current Assets
62.98
48.57
47.27
46.72
167.31
67.51
67.08
Current Investments
30.29
26.02
23.12
24.67
137.59
0.00
0.00
Inventories
2.80
2.60
2.62
2.38
2.30
17.02
12.45
Sundry Debtors
20.69
14.61
16.37
12.62
15.03
38.70
47.92
Cash & Bank
4.77
2.29
2.75
4.98
11.67
9.49
3.95
Other Current Assets
4.43
0.07
0.03
0.07
0.73
2.30
2.76
Short Term Loans & Adv.
4.06
2.98
2.38
2.00
0.22
1.30
2.71
Net Current Assets
48.07
36.87
39.28
39.87
106.84
1.28
45.90
Total Assets
126.12
110.42
115.73
126.23
176.92
152.99
134.82

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1.66
1.12
17.23
-7.62
-29.35
22.08
12.04
PBT
6.11
-9.32
-11.63
-0.95
-9.69
13.12
13.55
Adjustment
2.03
11.49
9.17
2.08
7.15
9.14
6.69
Changes in Working Capital
-6.47
-1.08
19.71
-8.70
-26.81
-0.17
-5.01
Cash after chg. in Working capital
1.68
1.09
17.25
-7.56
-29.35
22.08
15.24
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-0.02
0.03
-0.02
-0.06
0.00
0.00
-3.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-4.45
-1.53
-19.57
-31.20
41.02
-23.87
-20.42
Net Fixed Assets
-0.87
-0.66
-0.56
-2.00
96.84
-24.29
Net Investments
-4.21
-4.10
-20.40
68.35
-138.00
-0.71
Others
0.63
3.23
1.39
-97.55
82.18
1.13
Cash from Financing Activity
5.27
-0.04
0.11
-0.06
-9.49
7.33
7.31
Net Cash Inflow / Outflow
2.48
-0.45
-2.23
-38.87
2.18
5.54
-1.07
Opening Cash & Equivalents
2.29
2.75
4.98
43.85
9.49
3.95
5.03
Closing Cash & Equivalent
4.77
2.29
2.75
4.98
11.67
9.49
3.95

Financial Ratios

Standalone /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
78.86
75.44
81.07
89.54
85.53
62.30
55.09
ROA
4.36%
-7.86%
-9.25%
-0.19%
46.26%
7.29%
7.96%
ROE
4.95%
-8.59%
-9.91%
-0.25%
78.03%
13.52%
14.76%
ROCE
6.08%
-8.69%
-10.11%
-0.74%
76.95%
13.06%
15.35%
Fixed Asset Turnover
0.76
0.44
0.48
0.88
2.33
2.05
2.01
Receivable days
125.86
197.00
252.10
265.25
88.74
106.38
122.60
Inventory Days
19.22
33.17
43.50
44.88
31.91
36.20
31.85
Payable days
59.43
52.58
37.09
69.84
26.25
31.47
35.31
Cash Conversion Cycle
85.65
177.59
258.51
240.30
94.40
111.12
119.14
Total Debt/Equity
0.01
0.01
0.00
0.00
0.08
0.64
0.59
Interest Cover
15.68
-58.98
-183.29
-17.71
33.88
4.71
3.99

News Update:


  • Kilitch Drugs(India) - Quarterly Results
    7th Nov 2018, 19:27 PM

    Read More
  • Kilitch Drugs plans to start manufacturing operations in Ethopia
    25th Oct 2018, 08:56 AM

    The company has been successfully operating in the continent for three decades in providing pharmaceutical solutions

    Read More
  • Kilitch Drugs to focus on African markets with Cephalosporin injectable plant
    8th Aug 2018, 09:18 AM

    The unit will have a capacity of 20 million vials and commence operations in FY19-20

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.